The Autoimmune Pathway Study

Currently Recruiting

1 Jul 2026

Up to $9,200

Brisbane, Australia

We are exploring a new investigational drug that may be used in future studies for conditions linked to B cell activity. B cells play an important role in the immune system, and in some autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies, they can become overactive and contribute to inflammation.

This Phase 1 study is being conducted in healthy adults to understand how the investigational drug behaves in the body and to assess its safety and tolerability. Early studies like this help researchers gather the essential information needed about the drug so it can be tested in people living with autoimmune conditions.

Autoimmune conditions can significantly affect daily life, and researchers are continually working to understand new ways they might be treated in the future.

By taking part in this early study, you’ll be contributing to research that may guide the next steps in developing treatments for B cell–mediated autoimmune diseases.

Apply now Speak with us 1300 836 032

Join our clinical trial

This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study drug may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur.

Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions.

Join our clinical trial image

What to expect?

  • Particpation in a monitored clinical environment.
  • Study visits scheduled
  • Support from a professional medical team
  • Reimbursement for your time and commitment

Study schedule

 

Intake 1 In-clinic stay:

1 July 2026 – 5 July 2026

 Follow-up visits:

6 July 2026– 23 September 2026
Approx. 10 visits during this period
Intake 2 In-clinic stay:

6 July 2026 – 10 July 2026

 Follow-up visits:

11 July 2026 – 28 September 2026
Approx. 10 visits during this period

Study dates are subject to change. Our team will confirm details with you during the screening process.

Trial details

Study duration

  • 4 night stay
  • 10 follow-up visits
  • 6 phone calls

Study medication

Administered as an intravenous (IV) infusion

Additional eligibility

  • Weight between 60-95kg
  • Non-smokers or smoking less than 5 cigarettes per week
  • Prior smokers, must have a history of less than 20packs year history

Ethics

An independent ethics committee has approved this clinical trial.

Are you a match?

Age

18 - 55 years old

Remuneration

Up to $9,200 *with screening reimbursement.
Full details outlined in consent form.

Gender

Male or Female

Commitment

4 nights, 10 clinic visits

Register your interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg





















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information



Consent to Information Use and Future Contact